Phase 1 Lymphoma Trial, Recruiting NCT05296304 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Lymphoma
Back to Lymphoma

Phase 1 Lymphoma Trial, Recruiting

NCT05296304
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with a type of skin lymphoma called mycosis fungoides (MF), confirmed by a biopsy reviewed at Memorial Sloan Kettering Cancer Center (MSKCC)
  • Your condition is at Stage IB or more advanced, based on standard staging guidelines; having a related condition called Sézary syndrome at the same time is also allowed
  • Your skin disease is active enough to reach a minimum score of 10 on a specific skin assessment tool called the mSWAT (confirm with trial site)
  • You are physically well enough to carry out daily activities with little to no limitation (ranging from fully active to capable of self-care but unable to work)
  • You are able to understand and agree to take part in the study (give informed consent)
  • You may already be using certain creams or medications for itching (such as antihistamines), as long as these were started before joining the trial and no new ones are added after enrolling
  • Both patients who have never had systemic (whole-body) treatment and those whose disease has come back or not responded to previous treatment may be eligible

Who may not be able to join:

  • You have taken oral retinoid medications (a type of vitamin A-related drug) within the past 3 weeks
  • You have previously had a treatment called Total Skin Electron Beam (TSEB) radiation (previous targeted radiation to specific skin areas is acceptable)
  • You have also been diagnosed with certain other types of lymphoma or blood cancers at the same time
  • You have another cancer that is not a skin cancer at the same time
  • You are currently pregnant
  • You are unwilling to use two forms of barrier contraception (such as condoms or diaphragms) while taking the study medication
  • You are currently taking part in, or have recently (within 2 weeks) taken part in, another clinical trial involving an experimental drug or device
  • You have a hereditary condition causing very high fat (triglyceride) levels in your blood, or another health condition that would make a drug called bexarotene unsafe for you
  • You have taken steroid tablets or injections (systemic steroids) within the past 2 weeks, unless it is for an unrelated condition and the trial doctor approves
  • You are considered unlikely to follow the trial requirements, in the opinion of the trial doctor
  • You are currently taking a medication called gemfibrozil (used for cholesterol/triglycerides)
  • You are currently taking certain medications that interact with bexarotene, such as cyclosporine, tacrolimus, sirolimus, quinidine, or fentanyl (confirm with trial site about your specific medications)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Brandon Imber, MD, Memorial Sloan Kettering Cancer Center

Phone: 631-212-6346

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
16 March 2022
Est. completion
1 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of radiation dermatitis grade 3+

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov